• 1
    Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90: 152936.
  • 2
    Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998;90: 160920.
  • 3
    Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53: 13227.
  • 4
    Harris RE, Namboodiri KK, Farrar WB. Epidemiological study of nonsteroidal antiinflammatory drugs and breast cancer. Oncol Rep 1995;2: 5912.
  • 5
    Harris RE, Namboodiri KK, Stellman SD, Wynder EL. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prevent Med 1995;24: 11920.
  • 6
    Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7: 2035.
  • 7
    Fulton AM, Heppner GH. Relationships of prostaglandin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas. Cancer Res 1985;45: 477984.
  • 8
    Parrett ML, Harris RL, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997;10: 5038.
  • 9
    Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90: 44560.
  • 10
    Medina D. 1976. Mammary tumorigenesis in chemical carcinogen-treated mice. VI. Tumor producing capabilities of mammary dysplasias in BALB/cCrgl mice. J Natl Cancer Inst 1976;57: 11859.
  • 11
    Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 1983;3: 2231.
  • 12
    Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner M, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60: 130611.
  • 13
    Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87: 8039.
  • 14
    Fulton AM. Effects of indomethacin on the growth of cultured mammary tumors. Int J Cancer 1984;33: 3759.
  • 15
    Joarder FS, Abou-Issa H, Robertson FM, Parrett ML, Alshafie G, Harris RE. Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in female Sprague–Dawley rats. Oncol Rep 1997;4: 12713.
  • 16
    Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997;57: 26771.
  • 17
    Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF. Prostaglandins and breast cancer. Lancet 1977;2: 6246.
  • 18
    Bennett A, Berstock DA, Raja B, Stamford IF. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers. Br J Pharmacol 1979;66: 4515.
  • 19
    Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980;64: 10616.
  • 20
    Hortobagyi GN, Schultz P, Cailleau R, Samaan N, Blumenschien G. In vitro prostaglandin production by metastatic breast cancer. In: PowlesTW, BockmanRF, HonnKV, RamwellP. Prostaglandins and cancer: First International Conference. New York: Alan R. Liss, Inc., 1982. p 56772.
  • 21
    Karmali RA, Welt S, Thaler HT, Lefevre F. Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer 1983;48: 68996.
  • 22
    Liu X-H, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996;56: 51257.
  • 23
    Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999;94: 4515.
    Direct Link:
  • 24
    Hida T, Yatebe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58: 37614.
  • 25
    Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58: 48236.
  • 26
    Fulton AM. In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res 1984;44: 241620.
  • 27
    Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272: 340610.
  • 28
    Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999;274: 832834.
  • 29
    Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59: 435662.
  • 30
    Fulton AM, Gimotty P, Alonsozana E, Dorsey R, Kundu N. Elevated prostaglandin E2 levels in human breast cancer are associated with poor long-term survival. Proc AACR 2000;41: 574.
  • 31
    Fulton AM. Interactions of natural effector cells and prostaglandins in the control of metastasis. J Natl Cancer Inst 1987;78: 73541.